Nuvation Bio Inc. Interest Expense Nonoperating
Nuvation Bio Inc. (NUVB) reported Interest Expense Nonoperating of $6.76 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpenseNonoperating · last filed 2026-08-06
- Nuvation Bio Inc. interest expense nonoperating for the quarter ending 2026-06-30 was $6.76M, a 1505.46% increase year-over-year.
- Nuvation Bio Inc. interest expense nonoperating for the quarter ending 2026-03-31 was $6.71M, a 12322.22% increase year-over-year.
- Nuvation Bio Inc. interest expense nonoperating for the quarter ending 2025-12-31 was $6.67M, a 7397.75% increase year-over-year.
- Nuvation Bio Inc. interest expense nonoperating for the quarter ending 2025-09-30 was $6.53M, a 5345.00% increase year-over-year.
- Nuvation Bio Inc. interest expense nonoperating for fiscal 2025 was $13.68M, a 3912.32% increase from fiscal 2024.
- Nuvation Bio Inc. interest expense nonoperating for fiscal 2024 was $341.00K.
- Nuvation Bio Inc. interest expense nonoperating for fiscal 2023 was $0.00.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $6.76M 10-Q · filed 2026-08-06 | $13.47M 10-Q · filed 2026-08-06 | $20.14M derived: sum of 3 quarters · filed 2026-08-06 | $26.67M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $6.71M 10-Q · filed 2026-05-04 | $13.38M derived: sum of 2 quarters · filed 2026-05-04 | $19.91M derived: sum of 3 quarters · filed 2026-05-04 | $20.34M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $6.67M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $13.21M derived: sum of 2 quarters · filed 2026-03-02 | $13.63M derived: sum of 3 quarters · filed 2026-08-06 | $13.68M 10-K · filed 2026-03-02 |
| 2025-09-30 | $6.53M 10-Q · filed 2025-11-03 | $6.96M derived: sum of 2 quarters · filed 2026-08-06 | $7.01M 10-Q · filed 2025-11-03 | $7.10M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $421.00K 10-Q · filed 2026-08-06 | $475.00K 10-Q · filed 2026-08-06 | $564.00K derived: sum of 3 quarters · filed 2026-08-06 | $684.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $54.00K 10-Q · filed 2026-05-04 | $143.00K derived: sum of 2 quarters · filed 2026-05-04 | $263.00K derived: sum of 3 quarters · filed 2026-05-04 | $395.00K derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | $89.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $209.00K derived: sum of 2 quarters · filed 2026-03-02 | $341.00K derived: sum of 3 quarters · filed 2026-03-02 | $341.00K 10-K · filed 2026-03-02 |
| 2024-09-30 | $120.00K 10-Q · filed 2025-11-03 | $252.00K derived: sum of 2 quarters · filed 2025-11-03 | $252.00K 10-Q · filed 2025-11-03 | $252.00K derived: sum of 4 quarters · filed 2025-11-03 |
| 2024-06-30 | $132.00K 10-Q · filed 2025-08-07 | $132.00K 10-Q · filed 2025-08-07 | $132.00K derived: sum of 3 quarters · filed 2025-08-07 | $132.00K derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-07 | $0.00 derived: sum of 2 quarters · filed 2025-05-07 | $0.00 derived: sum of 3 quarters · filed 2025-05-07 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $0.00 derived: sum of 2 quarters · filed 2025-03-06 | $0.00 10-K · filed 2025-03-06 | |
| 2023-09-30 | $0.00 10-Q · filed 2024-11-06 | $0.00 10-Q · filed 2024-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |